OG of TechBio | Father/Husband/Scientist/Founder | Operating partner, Dimension | CEO, BOXBOX (stealth) | Founder/CEO of $RXRX through ‘25. Optimist.

Somewhere far, far away.
Joined August 2012
Chris Gibson retweeted
.@RecursionChris is joining DIMENSION as Operating Partner. Chris has already positively changed the arcs, ambitions, careers, and lives of many people, including my own. Excited to have him play a growing role in the future of @_DimensionCap and our portfolio!
9
10
1
136
14,076
Chris Gibson retweeted
News! @airstreet has raised $232,323,232 for Fund III to back AI-first companies from the earliest stages in the US and Europe. Now the largest solo GP venture firm in Europe. Our third epoch begins today. Join us!
184
59
24
1,036
180,643
Chris Gibson retweeted
🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence –  to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here: ir.recursion.com/news-releas…
9
23
6
120
11,988
Chris Gibson retweeted
Robinhood CEO @vladtenev reinvented their earnings calls after watching a YouTuber livestream one and apologize for how boring it was — then modeled the format after NBA Playoffs postgame interviews: “If I’m bored, the people watching this must be really bored.” “One year ago, we were doing earnings the old fashioned way. We had the Polycom. We had the script. I would read the script. We would take the questions over Polycom. Sell side analysts would be on the call exclusively.” “At one point the livestreamer kind of apologized to the audience. He's like, ‘I know it's a little bit dry. Sorry guys, but we'll get to Q&A soon.’” “What's an example, an analogy, something we could learn from and lift from another industry that is similar to this, but entertaining? I thought, it's kind of similar to an NBA Playoffs postgame interview — you've had something happen… It's either a good quarter, where you're beating and you have good things to say, or maybe it's a bad quarter. But it's kind of entertaining either way, right?” “Q4 of last year was our first earnings call where we did live video… Fast forward to our previous earnings call — it was at the Chase Center. We had live video. We had live Q&A where retail investors would basically livestream and ask their questions live.” “We went from hundreds of listeners on the old Polycom-style earnings to tens of thousands, maybe even 100,000 at the last one. It increased the actual audience of our earnings by multiple orders of magnitude.”
8
23
6
357
52,357
🔹 New data readout coming. Join us for a webinar on Dec. 8, 8:00 am ET / 6:00 am MT / 1:00 pm GMT where we’ll share updated clinical data from our ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP). REC-4881 is a potentially first-in-disease small molecule MEK 1/2 inhibitor that was identified using Recursion’s AI platform. ✨ Presenters include: ▪️ Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer and incoming CEO and President, Recursion ▪️ David Mauro, M.D., Ph.D., Chief Medical Officer, Recursion ▪️ Elizabeth Bruckheimer, Ph.D., Ph.D., Vice President of Clinical Development, Recursion ▪️ Jessica Stout, D.O., Assistant Clinical Professor, @UUtah School of Medicine ▪️ Alfred M. Cohen, MD, FACS, FASCRS, Former CMO, Cancer Prevention Pharmaceuticals; Prior Chief, Colorectal Service, @MSKCancerCenter ✨ The webinar will be streamed live here on X as well as on: ▪️ YouTube: youtube.com/@RecursionPharma ▪️ LinkedIn: linkedin.com/company/recursi… 👉 More: ir.recursion.com/news-releas…
4
6
5
52
16,426
Chris Gibson retweeted
Biotech has a narrative void. Biotech has potential for much much more futuristic and positive outcomes than most other companies. But biotech founders largely miss the opportunity, don’t have priors to narrative building, or see it as a waste of time. If you’re building a company in biotech, we all know that will take a long time. So to keep people engaged, interested, and inspired by what you’re doing, you need to continue to remind them about what you’re doing and why it will pull the future forward. Not only this, but with biotech funding much diminished from ZIRP highs, it’s hard to raise money. Thus you’re competing with every company on science (given) but also narrative. I’ve seen even small launches, blog posts, and preprints change the trajectory of countless companies and I want you to benefit too. And because of this companies have opportunities to paint their version of the future or let others capture the attention in their vertical and take the talent and funding. Why narrative matters: Eyeballs on your work means that you have a higher ability to raise money, hire the best people, and get in front of customers. The other side is that if you don’t take up narrative space other founders will. Nucleus is famous for this where there’s more scientifically legitimate groups such as Herasight and Orchid, but not controlling the narrative means that there’s room for Kian at Nucleus to entirely control story of IQ embryo selection. The Far-UVC space has a high mindshare,  controversial company, Nukit, which has allegations of unsubstantiated evidence. TLDR: if you don’t control the narrative, another company will. What Narrative is: - Distilled legibility of your vertical. - How your company will pull the future forward. - How the industry will reorient itself around you. - World building to bring people to the future your company will create. The best founders normally use all of these positionings while talking to different sets of investors, hires and customers and have a library of stories they add to as the company and its mindshare grow. Customers are normally compelled by distilled legibility (eg. what makes your protein designs better than X), whereas hires and investors will want more future building, value accrual, and world building positioning. Put another way, narrative is a way to increase your perception-to-reality ratio to raise more money and give your company a fighting chance for scaled success. Narrative makes Schelling points: We (especially @mhdempsey) have written a lot about category creation, delineating different properties that can lead to category creation such as technological moats, margin profiles, TAM expansion, industry turnover, and new markets. Expanding on this is the breakaway companies that are inextricably linked to categories such as “Palantir in government tech, Anduril in defense tech, OpenAI in frontier AI, Ginkgo Bioworks in Synbio, Recursion in computational bio, Bitcoin in crypto, Physical Intelligence in robotics, and more”. Distilled legibility has led all of these companies to become Schelling Points. How you get narrative capture: Write, post, have launch parties around model releases. Specifically the ways we see founders getting mindshare is by: - Releasing pre-prints. There are so many preprints by companies that it’s now become a standard of sorts. - Blogging about progress - @newlimit does an excellent job here releasing bi-monthly updates. Escalante blog also had great asthetic and opinion that circulated fairly far. - Writing the company’s masterplan. How success in one area begets new and bigger opportunities. This is now a trite example but Elon uses the vision piece to rebut the main critiques of the company, giving him more legitimacy for his goals. Brian Armstrong talked about how Coinbase will be worth more in the future than it is today. - Releasing internal communications. A famous internal memo at Slack came out about selling the innovation not the product and thinking about who you want your customers to become. This aligns employees and shows the world that you are building something different. From an internal founder memo at slack. If you're selling to Pharma, who do you want your Pharma customers to become? - Having launch parties to get persuadables onboard and understanding what you’re doing. The Boltz team is excellent at this and has launch presentations in multiple cities for every model release. - Launch videos for companies are becoming increasingly common. @themoldcompany and @alterego_io are great versions of this. You can also share launch videos for your high-impact advisors like @chaidiscovery . This is a call to action to please world build, please share your incredible progress, please share your master plans! The world will thank you.
23
39
11
271
71,042
Today, we’re reporting business updates and first quarter 2025 financial results. 🔹 Key updates include: ▪️ Prioritizing our pipeline: We’re delivering on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical and 1 preclinical program following a strategic, data-driven review. ▪️ Delivering for our partners: We achieved a fourth milestone in our collaboration with @sanofi for an orally active small-molecule lead with best-in-class potential in autoimmune diseases. We received $7 million for this milestone and are eligible for over $300 million in additional milestone payments for this program.  ▪️ Developing our platform and streamlining operations: We implemented meaningful synergies and streamlined operations while maintaining our capabilities, resulting in an expected cash runway until mid 2027. 🔹 Highlights from the report include:  ▪️ Preliminary data from our REC-4881 MEK 1/2 inhibitor clinical program for the treatment of familial adenomatous polyposis (FAP) showed a median 43% reduction (n=6) in polyp burden at the Week 13 assessment and an early safety profile that was generally consistent with that of prior MEK1/2 inhibitors, as shared in a late-breaking oral presentation May 4 at the 2025 @DDWMeeting. Learn more: ir.recursion.com/news-releas…  ▪️ Preclinical program REC-7735 for mutant breast cancer showed dose-dependent tumor regression in PI3Kα H1047R CDX models, with no elevation in insulin levels or hyperglycemia markers in preclinical models. Development candidate nomination is expected in 2H25.  ▪️ Preclinical program REV102, an ENPP1 inhibitor with first-in-class potential and part of a joint venture with @rallybio, is currently in IND-enabling studies for hypophosphatasia and shows preliminary efficacy comparable to enzyme replacement therapy in preclinical models. Phase 1 initiation is expected in 2H26. “Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said @RecursionChris, Co-Founder and CEO. "We are prioritizing high-potential programs to accelerate better treatments to patients, building on our platform's unique ability to learn and lead this transformative shift in drug discovery. Our deep appreciation goes to the patients and investigators whose participation is invaluable on this journey." 👉 Learn more: ir.recursion.com/news-releas… 👉 Tune in to our livestream (L)earnings Call today – May 5, 8am ET / 6am MT / 1pm BST – on our LinkedIn, X & YouTube accounts.
6
5
1
37
5,817
Chris Gibson retweeted
Founders who were PhD or post-doc in my lab at Berkeley, **largely funded by NSF / DoD grants**, start-up, market cap (collected by OpenAI Deep Research)
118
475
120
4,732
1,015,647
Chris Gibson retweeted
NVIDIA
@nvidia10 Mar 2025
A new #AI education initiative in the State of Utah, developed with NVIDIA, is set to advance the state’s commitment to workforce training and economic growth. nvda.ws/3XEge5w
22
33
2
188
42,052
RT @RecursionPharma: Najat Khan, PhD joined Recursion as Chief R&D and Chief Commercial Officer from a role leading the data science and #A…
2
11
AI visionary @Yoshua_Bengio - Turing Award-winner, CS professor at @UMontreal & our scientific advisor - discussed the role of #AI in drug discovery w/ @bmabey & @bertonearnshaw. The takeaway: “We are on the trajectory to build the tools to do as well as human scientists or better.” Extended conversation here: youtube.com/watch?v=_0uwwVVJ…
5
1
29
3,959
A close-up of #astrocytes - the most abundant #cell type in the human #brain - cultured & stained in our lab. #MicroscopyMonday
3
10
1
34
2,704
Chris Gibson retweeted
"It's our goal to prove that this kind of approach - about whether there's a better way to do drug discovery - that ultimately it will be faster to market, less expensive, more efficient," says @RecursionPharma CEO on using AI for pharmaceutical development:
5
14
3
51
17,608
“We came to London to seek the best talent in the world." Our #London office opening brought together #techbio leaders including @_danielcohen @nathanbenaich @mmbronstein & @zavaindar who said: "In 10 years...the term 'techbio' will be 'bio.'" recursion.com/careers
2
8
2
55
10,015
Watch our CEO Jensen Huang and @RecursionChris discuss the pivotal role of #AI in transforming industries, especially #biotech. Learn how computational power and innovative thinking are accelerating #drugdiscovery processes. #healthcare #supercomputers nvda.ws/3XODHC9
7
11
1,750
Today we opened our office in #London – the epicenter for #TechBio in Europe & home to one of the world’s best talent pools across #tech, #biology and #chemistry. @RecursionChris @howarddawber @mmbronstein @nathanbenaich @zavaindar @valence_ai @KristinaUlicna @_danielcohen
1
10
1
75
6,797
📣Attending @LDNTechWeek?! on Monday, @RecursionChris will be on a panel discussing "London: Europe's Hub for AI Innovation," alongside @DaniCMBelg from @GSK, @davidobarber from @ucl, moderated by @Roxana_M_Molina. Panel Info👉:bit.ly/3Xd6P5z #LTW24 #techbio #AI
5
1
10
4,590
not long ago, @recursionpharma and @valence_ai announced the opening of their london office to accelerate ai for drug discovery and design i'm really happy that we'll have @_danielcohen at @raais this year dan is president of valence labs, which is a gem of an org :-)
1
4
1
38
5,640
Replying to @WSJ
@WSJ's article by @asafitch on @nvidia highlighting $RXRX: "It’s really more about us and them working together to try and push the future of what biopharma looks like... For them to learn and for us to learn from each other.” @RecursionChris #techbio on.wsj.com/3TCV1r1
3
5
1,557